ReAlta Life Sciences Strengthens Board of Directors with Appointment of Two Accomplished Biotechnology Innovators
“We are delighted to welcome Dr. Baldoni and Dr. Van Gieson to our Board of Directors and look forward to their expertise as we continue to advance our EPICC platform beyond our current portfolio,” said Buzz Heidt, Chairman of ReAlta’s Board of Directors.
- “We are delighted to welcome Dr. Baldoni and Dr. Van Gieson to our Board of Directors and look forward to their expertise as we continue to advance our EPICC platform beyond our current portfolio,” said Buzz Heidt, Chairman of ReAlta’s Board of Directors.
- Dr. Baldoni’s Platform Technology and Science team supported the development of small molecules, biopharmaceuticals and cell and gene therapy modalities from discovery through commercialization.
- Dr. Baldoni stepped away from that leadership role in 2017 to start the first AI-driven drug discovery unit at GSK.
- After retiring from GSK in 2019, he spent a year as the Chief Technology Officer of a stealth AI-enabled drug discovery startup.